Global Human Granulocyte Colony-stimulating Factor Market Report, History and Forecast 2018-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Human Granulocyte Colony-stimulating Factor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Granulocyte Colony-stimulating Factor market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.

North America, Europe and Asia Pacific are the key regions for Human Granulocyte Colony-stimulating Factor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2029. 

Globally, Human Granulocyte Colony-stimulating Factor key manufacturers include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC and Wuzhong Pharmaceutical, etc. Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway are top 3 players and held % sales share in total in 2022.

Human Granulocyte Colony-stimulating Factor can be divided into 300μg/Dose, 150μg/Dose, 75μg/Dose and Others, etc. 300μg/Dose is the mainstream product in the market, accounting for % sales share globally in 2022.

Human Granulocyte Colony-stimulating Factor is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Human Granulocyte Colony-stimulating Factor industry development. In 2022, global % sales of Human Granulocyte Colony-stimulating Factor went into Hospital filed. 
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Human Granulocyte Colony-stimulating Factor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Manufacturers, Type, Application and Regions Listed in the Report:
By Company
    Chugai Pharmaceutical
    Kyowa Hakko Kirin
    Sanway
    GenSci
    SL PHARM
    Kexing Bioproducts
    Qilu Pharmaceutical
    CSPC
    Wuzhong Pharmaceutical
    Quangang Pharmaceutical
    Huabei Pharmaceutical
    Harbin Pharmaceutical
    Amoytop Biotech
    Jiuyuan Gene Engineering
    Four Rings Biopharmaceutical

Segment by Type
    300μg/Dose
    150μg/Dose
    75μg/Dose
    Others

Segment by Application
    Hospital
    Clinic

Segment by Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Human Granulocyte Colony-stimulating Factor market further:
Chapter 1: Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2: Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Granulocyte Colony-stimulating Factor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Granulocyte Colony-stimulating Factor industry.
Chapter 3: Historical (2018-2022) and forecast (2023-2029) volume and revenue analysis of Human Granulocyte Colony-stimulating Factor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4: Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10: Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Granulocyte Colony-stimulating Factor introduction, etc. Human Granulocyte Colony-stimulating Factor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11: Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12: Market Channel, Distributors and Customers are listed.
Chapter 13: QYResearch’s Conclusions of Human Granulocyte Colony-stimulating Factor market based on comprehensive survey.
Chapter 14: Methodology and Data Sources adopted by QYResearch.

 1 Human Granulocyte Colony-stimulating Factor Market Overview
    1.1 Human Granulocyte Colony-stimulating Factor Product Overview
    1.2 Human Granulocyte Colony-stimulating Factor Market Segment by Type
        1.2.1 300μg/Dose
        1.2.2 150μg/Dose
        1.2.3 75μg/Dose
        1.2.4 Others
    1.3 Global Human Granulocyte Colony-stimulating Factor Market Size by Type
        1.3.1 Global Human Granulocyte Colony-stimulating Factor Market Size Overview by Type (2018-2029)
        1.3.2 Global Human Granulocyte Colony-stimulating Factor Historic Market Size Review by Type (2018-2023)
        1.3.3 Global Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Type (2024-2029)
    1.4 Key Regions Market Size Segment by Type
        1.4.1 North America Human Granulocyte Colony-stimulating Factor Sales Breakdown by Type (2018-2023)
        1.4.2 Europe Human Granulocyte Colony-stimulating Factor Sales Breakdown by Type (2018-2023)
        1.4.3 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Breakdown by Type (2018-2023)
        1.4.4 Latin America Human Granulocyte Colony-stimulating Factor Sales Breakdown by Type (2018-2023)
        1.4.5 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Breakdown by Type (2018-2023)

 2 Global Human Granulocyte Colony-stimulating Factor Market Competition by Company
    2.1 Global Top Players by Human Granulocyte Colony-stimulating Factor Sales (2018-2023)
    2.2 Global Top Players by Human Granulocyte Colony-stimulating Factor Revenue (2018-2023)
    2.3 Global Top Players by Human Granulocyte Colony-stimulating Factor Price (2018-2023)
    2.4 Global Top Manufacturers Human Granulocyte Colony-stimulating Factor Manufacturing Base Distribution, Sales Area, Product Type
    2.5 Human Granulocyte Colony-stimulating Factor Market Competitive Situation and Trends
        2.5.1 Human Granulocyte Colony-stimulating Factor Market Concentration Rate (2018-2023)
        2.5.2 Global 5 and 10 Largest Manufacturers by Human Granulocyte Colony-stimulating Factor Sales and Revenue in 2022
    2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Granulocyte Colony-stimulating Factor as of 2022)
    2.7 Date of Key Manufacturers Enter into Human Granulocyte Colony-stimulating Factor Market
    2.8 Key Manufacturers Human Granulocyte Colony-stimulating Factor Product Offered
    2.9 Mergers & Acquisitions, Expansion

 3 Human Granulocyte Colony-stimulating Factor Status and Outlook by Region
    3.1 Global Human Granulocyte Colony-stimulating Factor Market Size and CAGR by Region: 2018 VS 2022 VS 2029
    3.2 Global Human Granulocyte Colony-stimulating Factor Historic Market Size by Region
        3.2.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2018-2023)
        3.2.2 Global Human Granulocyte Colony-stimulating Factor Sales in Value by Region (2018-2023)
        3.2.3 Global Human Granulocyte Colony-stimulating Factor Sales (Volume & Value) Price and Gross Margin (2018-2023)
    3.3 Global Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Region
        3.3.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2024-2029)
        3.3.2 Global Human Granulocyte Colony-stimulating Factor Sales in Value by Region (2024-2029)
        3.3.3 Global Human Granulocyte Colony-stimulating Factor Sales (Volume & Value), Price and Gross Margin (2024-2029)

 4 Global Human Granulocyte Colony-stimulating Factor by Application
    4.1 Human Granulocyte Colony-stimulating Factor Market Segment by Application
        4.1.1 Hospital
        4.1.2 Clinic
    4.2 Global Human Granulocyte Colony-stimulating Factor Market Size by Application
        4.2.1 Global Human Granulocyte Colony-stimulating Factor Market Size Overview by Application (2018-2029)
        4.2.2 Global Human Granulocyte Colony-stimulating Factor Historic Market Size Review by Application (2018-2023)
        4.2.3 Global Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Application (2024-2029)
    4.3 Key Regions Market Size Segment by Application
        4.3.1 North America Human Granulocyte Colony-stimulating Factor Sales Breakdown by Application (2018-2023)
        4.3.2 Europe Human Granulocyte Colony-stimulating Factor Sales Breakdown by Application (2018-2023)
        4.3.3 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Breakdown by Application (2018-2023)
        4.3.4 Latin America Human Granulocyte Colony-stimulating Factor Sales Breakdown by Application (2018-2023)
        4.3.5 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Breakdown by Application (2018-2023)

 5 North America Human Granulocyte Colony-stimulating Factor by Country
    5.1 North America Human Granulocyte Colony-stimulating Factor Historic Market Size by Country
        5.1.1 North America Human Granulocyte Colony-stimulating Factor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        5.1.2 North America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2018-2023)
        5.1.3 North America Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2018-2023)
    5.2 North America Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Country
        5.2.1 North America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2024-2029)
        5.2.2 North America Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2024-2029)

 6 Europe Human Granulocyte Colony-stimulating Factor by Country
    6.1 Europe Human Granulocyte Colony-stimulating Factor Historic Market Size by Country
        6.1.1 Europe Human Granulocyte Colony-stimulating Factor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        6.1.2 Europe Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2018-2023)
        6.1.3 Europe Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2018-2023)
    6.2 Europe Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Country
        6.2.1 Europe Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2024-2029)
        6.2.2 Europe Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2024-2029)

 7 Asia-Pacific Human Granulocyte Colony-stimulating Factor by Region
    7.1 Asia-Pacific Human Granulocyte Colony-stimulating Factor Historic Market Size by Region
        7.1.1 Asia-Pacific Human Granulocyte Colony-stimulating Factor Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
        7.1.2 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2018-2023)
        7.1.3 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales in Value by Region (2018-2023)
    7.2 Asia-Pacific Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Region
        7.2.1 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2024-2029)
        7.2.2 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales in Value by Region (2024-2029)

 8 Latin America Human Granulocyte Colony-stimulating Factor by Country
    8.1 Latin America Human Granulocyte Colony-stimulating Factor Historic Market Size by Country
        8.1.1 Latin America Human Granulocyte Colony-stimulating Factor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        8.1.2 Latin America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2018-2023)
        8.1.3 Latin America Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2018-2023)
    8.2 Latin America Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Country
        8.2.1 Latin America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2024-2029)
        8.2.2 Latin America Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2024-2029)

 9 Middle East and Africa Human Granulocyte Colony-stimulating Factor by Country
    9.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Historic Market Size by Country
        9.1.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
        9.1.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2018-2023)
        9.1.3 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2018-2023)
    9.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Forecasted Market Size by Country
        9.2.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2024-2029)
        9.2.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales in Value by Country (2024-2029)

 10 Company Profiles
    10.1 Chugai Pharmaceutical
        10.1.1 Chugai Pharmaceutical Company Information
        10.1.2 Chugai Pharmaceutical Introduction and Business Overview
        10.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.1.5 Chugai Pharmaceutical Recent Development
    10.2 Kyowa Hakko Kirin
        10.2.1 Kyowa Hakko Kirin Company Information
        10.2.2 Kyowa Hakko Kirin Introduction and Business Overview
        10.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Products Offered
        10.2.5 Kyowa Hakko Kirin Recent Development
    10.3 Sanway
        10.3.1 Sanway Company Information
        10.3.2 Sanway Introduction and Business Overview
        10.3.3 Sanway Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.3.4 Sanway Human Granulocyte Colony-stimulating Factor Products Offered
        10.3.5 Sanway Recent Development
    10.4 GenSci
        10.4.1 GenSci Company Information
        10.4.2 GenSci Introduction and Business Overview
        10.4.3 GenSci Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.4.4 GenSci Human Granulocyte Colony-stimulating Factor Products Offered
        10.4.5 GenSci Recent Development
    10.5 SL PHARM
        10.5.1 SL PHARM Company Information
        10.5.2 SL PHARM Introduction and Business Overview
        10.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Products Offered
        10.5.5 SL PHARM Recent Development
    10.6 Kexing Bioproducts
        10.6.1 Kexing Bioproducts Company Information
        10.6.2 Kexing Bioproducts Introduction and Business Overview
        10.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Products Offered
        10.6.5 Kexing Bioproducts Recent Development
    10.7 Qilu Pharmaceutical
        10.7.1 Qilu Pharmaceutical Company Information
        10.7.2 Qilu Pharmaceutical Introduction and Business Overview
        10.7.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.7.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.7.5 Qilu Pharmaceutical Recent Development
    10.8 CSPC
        10.8.1 CSPC Company Information
        10.8.2 CSPC Introduction and Business Overview
        10.8.3 CSPC Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.8.4 CSPC Human Granulocyte Colony-stimulating Factor Products Offered
        10.8.5 CSPC Recent Development
    10.9 Wuzhong Pharmaceutical
        10.9.1 Wuzhong Pharmaceutical Company Information
        10.9.2 Wuzhong Pharmaceutical Introduction and Business Overview
        10.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.9.5 Wuzhong Pharmaceutical Recent Development
    10.10 Quangang Pharmaceutical
        10.10.1 Quangang Pharmaceutical Company Information
        10.10.2 Quangang Pharmaceutical Introduction and Business Overview
        10.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.10.5 Quangang Pharmaceutical Recent Development
    10.11 Huabei Pharmaceutical
        10.11.1 Huabei Pharmaceutical Company Information
        10.11.2 Huabei Pharmaceutical Introduction and Business Overview
        10.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.11.5 Huabei Pharmaceutical Recent Development
    10.12 Harbin Pharmaceutical
        10.12.1 Harbin Pharmaceutical Company Information
        10.12.2 Harbin Pharmaceutical Introduction and Business Overview
        10.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.12.5 Harbin Pharmaceutical Recent Development
    10.13 Amoytop Biotech
        10.13.1 Amoytop Biotech Company Information
        10.13.2 Amoytop Biotech Introduction and Business Overview
        10.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Products Offered
        10.13.5 Amoytop Biotech Recent Development
    10.14 Jiuyuan Gene Engineering
        10.14.1 Jiuyuan Gene Engineering Company Information
        10.14.2 Jiuyuan Gene Engineering Introduction and Business Overview
        10.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Products Offered
        10.14.5 Jiuyuan Gene Engineering Recent Development
    10.15 Four Rings Biopharmaceutical
        10.15.1 Four Rings Biopharmaceutical Company Information
        10.15.2 Four Rings Biopharmaceutical Introduction and Business Overview
        10.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
        10.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Products Offered
        10.15.5 Four Rings Biopharmaceutical Recent Development

 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
    11.1 Human Granulocyte Colony-stimulating Factor Key Raw Materials
        11.1.1 Key Raw Materials
        11.1.2 Key Raw Materials Price
        11.1.3 Raw Materials Key Suppliers
    11.2 Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Human Granulocyte Colony-stimulating Factor Industrial Chain Analysis
    11.4 Human Granulocyte Colony-stimulating Factor Market Dynamics
        11.4.1 Human Granulocyte Colony-stimulating Factor Industry Trends
        11.4.2 Human Granulocyte Colony-stimulating Factor Market Drivers
        11.4.3 Human Granulocyte Colony-stimulating Factor Market Challenges
        11.4.4 Human Granulocyte Colony-stimulating Factor Market Restraints

 12 Market Strategy Analysis, Distributors
    12.1 Sales Channel
    12.2 Human Granulocyte Colony-stimulating Factor Distributors
    12.3 Human Granulocyte Colony-stimulating Factor Downstream Customers

 13 Research Findings and Conclusion

 14 Appendix
    14.1 Research Methodology
        14.1.1 Methodology/Research Approach
        14.1.2 Data Source
    14.2 Author Details
    14.3 Disclaimer

List of Tables
    Table 1. Major Company of 300μg/Dose
    Table 2. Major Company of 150μg/Dose
    Table 3. Major Company of 75μg/Dose
    Table 4. Major Company of Others
    Table 5. Global Human Granulocyte Colony-stimulating Factor Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
    Table 6. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (K Dose)
    Table 7. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type (2018-2023)
    Table 8. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US& Million)
    Table 9. Global Human Granulocyte Colony-stimulating Factor Market Share in Value by Type (2018-2023)
    Table 10. Global Human Granulocyte Colony-stimulating Factor Price by Type (2018-2023) & (USD/Dose)
    Table 11. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2024-2029) & (K Dose)
    Table 12. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type (2024-2029)
    Table 13. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2024-2029) & (US$ Million)
    Table 14. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type (2024-2029)
    Table 15. Global Human Granulocyte Colony-stimulating Factor Price by Type (2024-2029) & (USD/Dose)
    Table 16. North America Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (K Dose)
    Table 17. North America Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US$ Million)
    Table 18. Europe Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2018-2023)
    Table 19. Europe Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US$ Million)
    Table 20. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2018-2023)
    Table 21. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US$ Million)
    Table 22. Latin America Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2018-2023)
    Table 23. Latin America Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US$ Million)
    Table 24. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2018-2023)
    Table 25. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023) & (US$ Million)
    Table 26. Global Human Granulocyte Colony-stimulating Factor Sales by Company (2018-2023) & (K Dose)
    Table 27. Global Human Granulocyte Colony-stimulating Factor Sales Share by Company (2018-2023)
    Table 28. Global Human Granulocyte Colony-stimulating Factor Revenue by Company (2018-2023) & (US$ Million)
    Table 29. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Company (2018-2023)
    Table 30. Global Market Human Granulocyte Colony-stimulating Factor Price by Company (2018-2023) & (USD/Dose)
    Table 31. Global Human Granulocyte Colony-stimulating Factor Top Manufacturers Manufacturing Base Distribution and Sales Area
    Table 32. Global Human Granulocyte Colony-stimulating Factor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Granulocyte Colony-stimulating Factor as of 2022)
    Table 34. Date of Key Manufacturers Enter into Human Granulocyte Colony-stimulating Factor Market
    Table 35. Key Manufacturers Human Granulocyte Colony-stimulating Factor Product Type
    Table 36. Mergers & Acquisitions, Expansion Plans
    Table 37. Global Human Granulocyte Colony-stimulating Factor Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (K Dose)
    Table 39. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Region (2018-2023)
    Table 40. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (US$ Million)
    Table 41. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Region (2018-2023)
    Table 42. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 43. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2029) & (K Dose)
    Table 44. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Region (2024-2029)
    Table 45. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2029) & (US$ Million)
    Table 46. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Region (2024-2029)
    Table 47. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2024-2029)
    Table 48. Global Human Granulocyte Colony-stimulating Factor Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 49. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (K Dose)
    Table 50. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application (2018-2023)
    Table 51. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 52. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application (2018-2023)
    Table 53. Global Human Granulocyte Colony-stimulating Factor Price by Application (2018-2023) & (USD/Dose)
    Table 54. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2024-2029) & (K Dose)
    Table 55. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application (2024-2029)
    Table 56. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2024-2029) & (US$ Million)
    Table 57. Global Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application (2024-2029)
    Table 58. Global Human Granulocyte Colony-stimulating Factor Price by Application (2024-2029) & (USD/Dose)
    Table 59. North America Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) (K Dose) 
    Table 60. North America Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 61. Europe Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) (K Dose) 
    Table 62. Europe Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 63. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) (K Dose) 
    Table 64. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 65. Latin America Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) (K Dose) 
    Table 66. Latin America Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 67. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) (K Dose) 
    Table 68. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023) & (US$ Million)
    Table 69. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
    Table 70. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2018-2023)
    Table 71. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (US$ Million)
    Table 72. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2018-2023)
    Table 73. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (K Dose)
    Table 74. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2024-2029)
    Table 75. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (US$ Million)
    Table 76. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2024-2029)
    Table 77. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
    Table 78. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2018-2023)
    Table 79. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (US$ Million)
    Table 80. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2018-2023)
    Table 81. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (K Dose)
    Table 82. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2024-2029)
    Table 83. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (US$ Million)
    Table 84. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2024-2029)
    Table 85. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (K Dose)
    Table 86. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Region (2018-2023)
    Table 87. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (US$ Million)
    Table 88. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Region (2018-2023)
    Table 89. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2029) & (K Dose)
    Table 90. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Region (2024-2029)
    Table 91. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2029) & (US$ Million)
    Table 92. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Region (2024-2029)
    Table 93. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
    Table 94. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2018-2023)
    Table 95. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (US$ Million)
    Table 96. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2018-2023)
    Table 97. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (K Dose)
    Table 98. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2024-2029)
    Table 99. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (US$ Million)
    Table 100. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2024-2029)
    Table 101. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
    Table 102. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2018-2023)
    Table 103. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (US$ Million)
    Table 104. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2018-2023)
    Table 105. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (K Dose)
    Table 106. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Country (2024-2029)
    Table 107. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2029) & (US$ Million)
    Table 108. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Country (2024-2029)
    Table 109. Chugai Pharmaceutical Company Information
    Table 110. Chugai Pharmaceutical Introduction and Business Overview
    Table 111. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 112. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 113. Chugai Pharmaceutical Recent Development
    Table 114. Kyowa Hakko Kirin Company Information
    Table 115. Kyowa Hakko Kirin Introduction and Business Overview
    Table 116. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 117. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product
    Table 118. Kyowa Hakko Kirin Recent Development
    Table 119. Sanway Company Information
    Table 120. Sanway Introduction and Business Overview
    Table 121. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 122. Sanway Human Granulocyte Colony-stimulating Factor Product
    Table 123. Sanway Recent Development
    Table 124. GenSci Company Information
    Table 125. GenSci Introduction and Business Overview
    Table 126. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 127. GenSci Human Granulocyte Colony-stimulating Factor Product
    Table 128. GenSci Recent Development
    Table 129. SL PHARM Company Information
    Table 130. SL PHARM Introduction and Business Overview
    Table 131. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 132. SL PHARM Human Granulocyte Colony-stimulating Factor Product
    Table 133. SL PHARM Recent Development
    Table 134. Kexing Bioproducts Company Information
    Table 135. Kexing Bioproducts Introduction and Business Overview
    Table 136. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 137. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product
    Table 138. Kexing Bioproducts Recent Development
    Table 139. Qilu Pharmaceutical Company Information
    Table 140. Qilu Pharmaceutical Introduction and Business Overview
    Table 141. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 142. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 143. Qilu Pharmaceutical Recent Development
    Table 144. CSPC Company Information
    Table 145. CSPC Introduction and Business Overview
    Table 146. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 147. CSPC Human Granulocyte Colony-stimulating Factor Product
    Table 148. CSPC Recent Development
    Table 149. Wuzhong Pharmaceutical Company Information
    Table 150. Wuzhong Pharmaceutical Introduction and Business Overview
    Table 151. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 152. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 153. Wuzhong Pharmaceutical Recent Development
    Table 154. Quangang Pharmaceutical Company Information
    Table 155. Quangang Pharmaceutical Introduction and Business Overview
    Table 156. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 157. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 158. Quangang Pharmaceutical Recent Development
    Table 159. Huabei Pharmaceutical Company Information
    Table 160. Huabei Pharmaceutical Introduction and Business Overview
    Table 161. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 162. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 163. Huabei Pharmaceutical Recent Development
    Table 164. Harbin Pharmaceutical Company Information
    Table 165. Harbin Pharmaceutical Introduction and Business Overview
    Table 166. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 167. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 168. Harbin Pharmaceutical Recent Development
    Table 169. Amoytop Biotech Company Information
    Table 170. Amoytop Biotech Introduction and Business Overview
    Table 171. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 172. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product
    Table 173. Amoytop Biotech Recent Development
    Table 174. Jiuyuan Gene Engineering Company Information
    Table 175. Jiuyuan Gene Engineering Introduction and Business Overview
    Table 176. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 177. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product
    Table 178. Jiuyuan Gene Engineering Recent Development
    Table 179. Four Rings Biopharmaceutical Company Information
    Table 180. Four Rings Biopharmaceutical Introduction and Business Overview
    Table 181. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2023)
    Table 182. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product
    Table 183. Four Rings Biopharmaceutical Recent Development
    Table 184. Key Raw Materials Lists
    Table 185. Raw Materials Key Suppliers Lists
    Table 186. Human Granulocyte Colony-stimulating Factor Market Trends
    Table 187. Human Granulocyte Colony-stimulating Factor Market Drivers
    Table 188. Human Granulocyte Colony-stimulating Factor Market Challenges
    Table 189. Human Granulocyte Colony-stimulating Factor Market Restraints
    Table 190. Human Granulocyte Colony-stimulating Factor Distributors List
    Table 191. Human Granulocyte Colony-stimulating Factor Downstream Customers
    Table 192. Research Programs/Design for This Report
    Table 193. Key Data Information from Secondary Sources
    Table 194. Key Data Information from Primary Sources
List of Figures
    Figure 1. Human Granulocyte Colony-stimulating Factor Product Picture
    Figure 2. Global Human Granulocyte Colony-stimulating Factor Market Size, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 3. Global Human Granulocyte Colony-stimulating Factor Market Size Status and Outlook (2018-2029) & (US$ Million)
    Figure 4. Global Human Granulocyte Colony-stimulating Factor Sales Status and Outlook (2018-2029) & (K Dose)
    Figure 5. Product Picture of 300μg/Dose
    Figure 6. Global 300μg/Dose Sales YoY Growth (2018-2029) & (K Dose)
    Figure 7. Product Picture of 150μg/Dose
    Figure 8. Global 150μg/Dose Sales YoY Growth (2018-2029) & (K Dose)
    Figure 9. Product Picture of 75μg/Dose
    Figure 10. Global 75μg/Dose Sales YoY Growth (2018-2029) & (K Dose)
    Figure 11. Product Picture of Others
    Figure 12. Global Others Sales YoY Growth (2018-2029) & (K Dose)
    Figure 13. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2029) & (US$ Million)
    Figure 14. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type in 2022 & 2029
    Figure 15. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type in 2022
    Figure 16. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type in 2022
    Figure 17. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type in 2022
    Figure 18. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type in 2022
    Figure 19. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type in 2022
    Figure 20. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type in 2022
    Figure 21. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type in 2022
    Figure 22. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type in 2022
    Figure 23. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Type in 2022
    Figure 24. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Type in 2022
    Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Granulocyte Colony-stimulating Factor Sales in 2022
    Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Granulocyte Colony-stimulating Factor Revenue in 2022
    Figure 27. Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
    Figure 28. Product Picture of Hospital
    Figure 29. Global Hospital Sales YoY Growth (2018-2029) & (K Dose)
    Figure 30. Product Picture of Clinic
    Figure 31. Global Clinic Sales YoY Growth (2018-2029) & (K Dose)
    Figure 32. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2029) & (US$ Million)
    Figure 33. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application in 2022 & 2029
    Figure 34. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application in 2022
    Figure 35. North America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application in 2022
    Figure 36. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application in 2022
    Figure 37. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application in 2022
    Figure 38. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application in 2022
    Figure 39. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application in 2022
    Figure 40. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Volume by Application in 2022
    Figure 41. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application in 2022
    Figure 42. Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales Market Share in Value by Application in 2022
    Figure 43. Key Raw Materials Price
    Figure 44. Human Granulocyte Colony-stimulating Factor Manufacturing Cost Structure
    Figure 45. Human Granulocyte Colony-stimulating Factor Industrial Chain Analysis
    Figure 46. Channels of Distribution
    Figure 47. Distributors Profiles
    Figure 48. Bottom-up and Top-down Approaches for This Report
    Figure 49. Data Triangulation
    Figure 50. Key Executives Interviewed

Human Granulocyte Colony-stimulating Factor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Granulocyte Colony-stimulating Factor market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.

North America, Europe and Asia Pacific are the key regions for Human Granulocyte Colony-stimulating Factor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2029. 

Globally, Human Granulocyte Colony-stimulating Factor key manufacturers include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC and Wuzhong Pharmaceutical, etc. Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway are top 3 players and held % sales share in total in 2022.

Human Granulocyte Colony-stimulating Factor can be divided into 300μg/Dose, 150μg/Dose, 75μg/Dose and Others, etc. 300μg/Dose is the mainstream product in the market, accounting for % sales share globally in 2022.

Human Granulocyte Colony-stimulating Factor is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Human Granulocyte Colony-stimulating Factor industry development. In 2022, global % sales of Human Granulocyte Colony-stimulating Factor went into Hospital filed. 
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Human Granulocyte Colony-stimulating Factor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Manufacturers, Type, Application and Regions Listed in the Report:
By Company
    Chugai Pharmaceutical
    Kyowa Hakko Kirin
    Sanway
    GenSci
    SL PHARM
    Kexing Bioproducts
    Qilu Pharmaceutical
    CSPC
    Wuzhong Pharmaceutical
    Quangang Pharmaceutical
    Huabei Pharmaceutical
    Harbin Pharmaceutical
    Amoytop Biotech
    Jiuyuan Gene Engineering
    Four Rings Biopharmaceutical

Segment by Type
    300μg/Dose
    150μg/Dose
    75μg/Dose
    Others

Segment by Application
    Hospital
    Clinic

Segment by Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Human Granulocyte Colony-stimulating Factor market further:
Chapter 1: Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2: Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Granulocyte Colony-stimulating Factor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Granulocyte Colony-stimulating Factor industry.
Chapter 3: Historical (2018-2022) and forecast (2023-2029) volume and revenue analysis of Human Granulocyte Colony-stimulating Factor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4: Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10: Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Granulocyte Colony-stimulating Factor introduction, etc. Human Granulocyte Colony-stimulating Factor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11: Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12: Market Channel, Distributors and Customers are listed.
Chapter 13: QYResearch’s Conclusions of Human Granulocyte Colony-stimulating Factor market based on comprehensive survey.
Chapter 14: Methodology and Data Sources adopted by QYResearch.